Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Feb;117(4):750–756. doi: 10.1111/j.1476-5381.1996.tb15254.x

Effects of 8-OHDPAT and 5-HT1A antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing.

M K Mundey 1, A Fletcher 1, C A Marsden 1
PMCID: PMC1909345  PMID: 8646424

Abstract

1. The effects of 5-HT1A antagonists on guinea-pig behaviour and dorsal raphe neuronal activity were investigated. 2. WAY100135 (10 mg kg-1, s.c.) and WAY100635 (1 mg kg-1, s.c.) significantly reduced the behaviours induced by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OHDPAT) (1 mg kg-1, s.c.) indicative of post-synaptic 5-HT1A receptor antagonism. WAY100635 (10 mg kg-1, s.c.) alone induced ear twitches, which were antagonized by ketanserin (1 mg kg-1, s.c.), but no other overt behaviours. 3. WAY100635 (0.125 mg kg-1, i.v.) produced a right-ward shift in the dose-related inhibition of neuronal firing by 8-OHDPAT (5-100 micrograms kg-1, i.v.) but did not affect the maximum inhibition induced by 8-OHDPAT indicating competitive antagonism between 8-OHDPAT and WAY100635 at the 5-HT1A somato-dendritic autoreceptor in the dorsal raphe nucleus of the guinea-pig. WAY100635 also produced a dose-related increase in the basal firing of 5-HT neurones in the dorsal raphe nucleus and restored the firing of dorsal raphe neurones previously inhibited by 8-OHDPAT (10 micrograms kg-1, i.v.). 4. The results indicate that WAY100635 is a competitive 5-HT1A antagonist in the guinea-pig. Furthermore WAY100635 can increase 5-HT neuronal firing, suggesting that it blocks a 5-HT1A receptor-mediated inhibitory tone acting on guinea-pig 5-HT neurones resulting in increased 5-HT release and 5-HT2 receptor-mediated behaviours.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvidsson L. E., Hacksell U., Nilsson J. L., Hjorth S., Carlsson A., Lindberg P., Sanchez D., Wikstrom H. 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem. 1981 Aug;24(8):921–923. doi: 10.1021/jm00140a002. [DOI] [PubMed] [Google Scholar]
  2. Baxter G., Kennett G., Blaney F., Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci. 1995 Mar;16(3):105–110. doi: 10.1016/s0165-6147(00)88991-9. [DOI] [PubMed] [Google Scholar]
  3. Bedard P., Pycock C. J. "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology. 1977 Oct;16(10):663–670. doi: 10.1016/0028-3908(77)90117-4. [DOI] [PubMed] [Google Scholar]
  4. Björk L., Cornfield L. J., Nelson D. L., Hillver S. E., Andén N. E., Lewander T., Hacksell U. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther. 1991 Jul 1;258(1):58–65. [PubMed] [Google Scholar]
  5. Deakin J. F., Green A. R. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol. 1978 Oct;64(2):201–209. doi: 10.1111/j.1476-5381.1978.tb17290.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dourish C. T., Hutson P. H., Curzon G. Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Brain Res Bull. 1985 Oct;15(4):377–384. doi: 10.1016/0361-9230(85)90005-x. [DOI] [PubMed] [Google Scholar]
  7. Fletcher A., Bill D. J., Bill S. J., Cliffe I. A., Dover G. M., Forster E. A., Haskins J. T., Jones D., Mansell H. L., Reilly Y. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmacol. 1993 Jun 24;237(2-3):283–291. doi: 10.1016/0014-2999(93)90280-u. [DOI] [PubMed] [Google Scholar]
  8. Fone K. C., Robinson A. J., Marsden C. A. Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. Br J Pharmacol. 1991 Jun;103(2):1547–1555. doi: 10.1111/j.1476-5381.1991.tb09825.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grahame-Smith D. G. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol. 1971 Dec;43(4):856–864. doi: 10.1111/j.1476-5381.1971.tb07222.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grahame-Smith D. G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem. 1971 Jun;18(6):1053–1066. doi: 10.1111/j.1471-4159.1971.tb12034.x. [DOI] [PubMed] [Google Scholar]
  11. Green A. R., Hall J. E., Rees A. R. A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists. Br J Pharmacol. 1981 Jul;73(3):703–719. doi: 10.1111/j.1476-5381.1981.tb16806.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Green A. R., Tordoff A. F., Bloomfield M. R. Elevation of brain GABA concentrations with amino-oxyacetic acid; effect on the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. J Neural Transm. 1976;39(1-2):103–112. doi: 10.1007/BF01248769. [DOI] [PubMed] [Google Scholar]
  13. HESS S. M., DOEPFNER W. Behavioral effects and brain amine content in rats. Arch Int Pharmacodyn Ther. 1961 Nov 1;134:89–99. [PubMed] [Google Scholar]
  14. Jolas T., Haj-Dahmane S., Lanfumey L., Fattaccini C. M., Kidd E. J., Adrien J., Gozlan H., Guardiola-Lemaitre B., Hamon M. (-)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):453–463. doi: 10.1007/BF00166735. [DOI] [PubMed] [Google Scholar]
  15. Klawans H. L., Jr, Goetz C., Weiner W. J. 5-Hydroxytryptophan-induced myoclonus in guinea pigs and the possible role of serotonin in infantile myoclonus. Neurology. 1973 Nov;23(11):1234–1240. doi: 10.1212/wnl.23.11.1234. [DOI] [PubMed] [Google Scholar]
  16. Lovenberg T. W., Baron B. M., de Lecea L., Miller J. D., Prosser R. A., Rea M. A., Foye P. E., Racke M., Slone A. L., Siegel B. W. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993 Sep;11(3):449–458. doi: 10.1016/0896-6273(93)90149-l. [DOI] [PubMed] [Google Scholar]
  17. Luscombe G., Jenner P., Marsden C. D. Myoclonus in guniea pigs is induced by indole-containing but not piperazine-containing 5HT agonists. Life Sci. 1982 Apr 26;30(17):1487–1494. doi: 10.1016/0024-3205(82)90563-x. [DOI] [PubMed] [Google Scholar]
  18. Luscombe G., Jenner P., Marsden C. D. Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain. Neuropharmacology. 1981 Sep;20(9):819–831. doi: 10.1016/0028-3908(81)90074-5. [DOI] [PubMed] [Google Scholar]
  19. Luscombe G., Jenner P., Marsden C. D. Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems. Neuropharmacology. 1982 Dec;21(12):1257–1265. doi: 10.1016/0028-3908(82)90130-7. [DOI] [PubMed] [Google Scholar]
  20. Martin L. L., Sanders-Bush E. Comparison of the pharmacological characteristics of 5 HT1 and 5 HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(3):165–170. doi: 10.1007/BF00505480. [DOI] [PubMed] [Google Scholar]
  21. Mundey M. K., Fletcher A., Marsden C. A. Effect of the putative 5-HT1A antagonists WAY100135 and SDZ 216-525 on 5-HT neuronal firing in the guinea-pig dorsal raphe nucleus. Neuropharmacology. 1994 Jan;33(1):61–66. doi: 10.1016/0028-3908(94)90097-3. [DOI] [PubMed] [Google Scholar]
  22. Nakahata N., Ishimoto H., Mizuno K., Ohizumi Y., Nakanishi H. Dual effects of mastoparan on intracellular free Ca2+ concentrations in human astrocytoma cells. Br J Pharmacol. 1994 May;112(1):299–303. doi: 10.1111/j.1476-5381.1994.tb13068.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ortmann R., Waldmeier P. C., Radeke E., Felner A., Delini-Stula A. The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn Schmiedebergs Arch Pharmacol. 1980 Mar;311(2):185–192. doi: 10.1007/BF00510258. [DOI] [PubMed] [Google Scholar]
  24. Tricklebank M. D., Forler C., Fozard J. R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 1984 Nov 13;106(2):271–282. doi: 10.1016/0014-2999(84)90714-3. [DOI] [PubMed] [Google Scholar]
  25. Trulson M. E., Jacobs B. L. Dose-response relationships between systemically administered L-tryptophan or L-5-hydroxytryptophan and raphe unit activity in the rat. Neuropharmacology. 1976 Jun;15(6):339–344. doi: 10.1016/0028-3908(76)90080-0. [DOI] [PubMed] [Google Scholar]
  26. Volkman P. H., Lorens S. A., Kindel G. H., Ginos J. Z. L-5-Hydroxytryptophan-induced myoclonus in guinea pigs: a model for the study of central serotonin-dopamine interactions. Neuropharmacology. 1978 Nov;17(11):947–955. doi: 10.1016/0028-3908(78)90137-5. [DOI] [PubMed] [Google Scholar]
  27. Welsh N. J., Shankley N. P., Black J. W. Comparative analysis of the vagal stimulation of gastric acid secretion in rodent isolated stomach preparations. Br J Pharmacol. 1994 May;112(1):93–96. doi: 10.1111/j.1476-5381.1994.tb13035.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yamada J., Sugimoto Y., Horisaka K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol. 1988 Sep 23;154(3):299–304. doi: 10.1016/0014-2999(88)90205-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES